SCHEMBL3500033

SCHEMBL3500033

CCOC(=O)c1cc2cc(-c3ccc(C)cc3)ccc2s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.56
ALDH1A1 P00352 2/20 0.56
PKM P14618 1/20 0.56
F9 P00740 5/20 0.49
F10 P00742 3/20 0.49
TRPM8 Q7Z2W7 1/20 0.48
PTPN2 P17706 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
GAA P10253 1/20 0.43
TARBP2 Q15633 1/20 0.43
KDM4E B2RXH2 2/20 0.42
HPGD P15428 1/20 0.42
MAPK14 Q16539 1/20 0.42
NPC1 O15118 1/20 0.42
CASP3 P42574 1/20 0.42
RAB9A P51151 1/20 0.42
ATM Q13315 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SENP7 Q9BQF6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3498021 0.89 MAPT (0.50) MAPTALDH1A1PKMF9F10
SCHEMBL3498454 0.89 MAPK14 (0.54) MAPTALDH1A1PKMF9F10
SCHEMBL1205380 0.88 PTPN2 (0.51) MAPTALDH1A1PKMTRPM8PTPN2
SCHEMBL3498640 0.88 MAPT (0.52) MAPTALDH1A1PKMF9F10
SCHEMBL3496798 0.87 PRKCI (0.46) MAPTALDH1A1PKMF9F10
SCHEMBL3499196 0.86 MAPT (0.53) MAPTALDH1A1PKMF9F10
SCHEMBL17149255 0.86 MAPT (0.62) MAPTALDH1A1PKMF9F10
SCHEMBL3500699 0.85 F9 (0.49) MAPTALDH1A1PKMF9F10
SCHEMBL3499504 0.85 F9 (0.47) MAPTALDH1A1PKMF9F10
SCHEMBL3498274 0.84 CDC7 (0.50) MAPTALDH1A1PKMF9F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 MAPT 4820/4885ALDH1A1 3047/4885PKM 4229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.